Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review.

Knight SR, Morris PJ.

Transplantation. 2008 Jun 27;85(12):1675-85. doi: 10.1097/TP.0b013e3181744199. Review.

PMID:
18580456
2.

Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.

Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y.

Clin Ther. 2008 Apr;30(4):673-83.

PMID:
18498916
3.

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, Ehninger G, Schleyer E, Bornhäuser M.

Bone Marrow Transplant. 2008 Jul;42(2):113-20. doi: 10.1038/bmt.2008.85. Epub 2008 Mar 24.

PMID:
18362900
4.

Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT).

Jacobson P, Huang J, Rydholm N, Tran M, Defor T, Tolar J, Orchard PJ.

J Clin Pharmacol. 2008 Apr;48(4):485-94. doi: 10.1177/0091270007313326. Epub 2008 Feb 22.

PMID:
18296555
5.
6.

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.

Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P.

Am J Transplant. 2007 Nov;7(11):2496-503. Epub 2007 Oct 1.

7.

Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.

Grosskreutz C, Scigliano E, Osman K, Isola L.

Transplantation. 2007 Sep 15;84(5):598-604.

PMID:
17876272
8.

Therapeutic monitoring of mycophenolate mofetil.

Jeong H, Kaplan B.

Clin J Am Soc Nephrol. 2007 Jan;2(1):184-91. Epub 2006 Nov 8. Review. No abstract available.

9.

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE.

Blood. 2007 Oct 15;110(8):3064-70. Epub 2007 Jun 14.

10.

Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.

van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M, Löwenberg B, Mathot RA, Armstrong VW, van Gelder T.

Ther Drug Monit. 2007 Jun;29(3):353-60.

PMID:
17529894
11.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Staatz CE, Tett SE.

Clin Pharmacokinet. 2007;46(1):13-58. Review.

PMID:
17201457
12.

Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.

Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, McGlave P, Weisdorf D.

J Clin Pharmacol. 2007 Jan;47(1):6-12.

PMID:
17192496
13.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34.

14.

Therapeutic drug monitoring of mycophenolate mofetil in transplantation.

van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD.

Ther Drug Monit. 2006 Apr;28(2):145-54. Review.

PMID:
16628123
15.

Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.

Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R.

Biol Blood Marrow Transplant. 2006 Apr;12(4):454-65.

16.

Individualization of mycophenolate mofetil dose in renal transplant recipients.

van Hest RM, Hesselink DA, Vulto AG, Mathot RA, van Gelder T.

Expert Opin Pharmacother. 2006 Mar;7(4):361-76. Review.

PMID:
16503809
17.

Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation.

Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, Tan Y, Long J, Remmel R, Sawchuk R, McGlave P.

Clin Pharmacol Ther. 2005 Nov;78(5):486-500.

PMID:
16321615
18.

Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT, Cole S, Nash RA, Storb RF, Georges GE.

Blood. 2005 Dec 15;106(13):4381-8. Epub 2005 Sep 6.

19.
20.

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.

Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505.

Items per page

Supplemental Content

Write to the Help Desk